Huntington's Disease Market to Witness Upsurge in Growth at a Tremendous CAGR of 18.4% During the Study P

The growth of the Huntington's disease market is expected to be mainly driven by less competitive scenarios, entry of innovative emerging therapies, rising prevalence, and geriatric population, increasing initiatives for R&D, and the advent of genetic testing

LAS VEGAS, Jan. 25, 2023 /PRNewswire/ -- DelveInsight's Huntington's Disease Market Insightsreport includes a comprehensive understanding of current treatment practices, Huntington's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Huntington's Disease Market Report

• As per DelveInsight analysis, the Huntington's diseasemarket size in the 7MM was approximately USD 199 million in 2021.
• According to the assessment done by DelveInsight, the estimated total Huntington's diseaseprevalent population in the 7MM was approximately 80K in 2021.
• Globally, leading Huntington's diseasecompanies such as Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Wave life sciences, Takeda, Medesis Pharm, Ionis Pharmaceuticals, PTC Therapeutics, Novartis, Neurimmune Therapeutics, SOLA Biosciences, Roche, AOP Orphan, Azevan Pharmaceuticals, Asklepios BioPharmaceutical, BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG,Arvinas, Atalanta Therapeutics, Anima Biotech, and others are developing novel Huntington's Disease drugs that can be available in the Huntington's disease market in the coming years.
• The promising Huntington's diseasetherapies in the pipeline include ACR-16 (pridopidine), INGREZZA (valbenazine/NBI-98854), ANX005, SOM3355 (bevantolol), VX15/2503 (pepinemab), SAGE-718, AMT-130 (rAAV5-miHTT), WVE-003 (mHTT SNP3), NP03 (nanolithium)/NanosiRNA, and others.
• In October 2021, SOM Biotech announced that the US FDA had granted Orphan Drug Designation (ODD) for SOM3355 for the treatment of chorea movements in HD.
• In October 2021, Annexon was granted orphan drug designation for the treatment of Huntington's disease by the US FDA.
• In September 2021, Sage Therapeutics announced that the US FDA had granted Fast Track Designation to SAGE-718 for development as a potential treatment for HD.
• In August 2016, the US FDA granted Fast-track Designation and Orphan drug designation to pepinemab for the treatment of Huntington's disease.

Discover which therapies are expected to grab the major Huntington's diseasemarket share @ Huntington's Disease Market Report